Erratum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 (Nature (2015) 522 (487-491) DOI: 10.1038/nature14411);Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Nature

Volumn 522, Issue 7557, 2015, Pages 487-491

  Caskey, Marina ^a   Klein, Florian ^a   Lorenzi, Julio C C ^a   Seaman, Michael S ^b   West, Anthony P ^c   Buckley, Noreen ^a   Kremer, Gisela ^d,e   Nogueira, Lilian ^a   Braunschweig, Malte ^a,f   Scheid, Johannes F ^a   Horwitz, Joshua A ^a   Shimeliovich, Irina ^a   Ben Avraham, Sivan ^a   Witmer Pack, Maggi ^a   Platten, Martin ^d,g   Lehmann, Clara ^d,g   Burke, Leah A ^a,h   Hawthorne, Thomas ⁱ   Gorelick, Robert J ^j   Walker, Bruce D ^k   Keler, Tibor ⁱ   Gulick, Roy M ^h   Fätkenheuer, Gerd ^d,g   Schlesinger, Sarah J ^a   Nussenzweig, Michel C ^a   more..

^a ROCKEFELLER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ Celldex Therapeutics Inc   (United Kingdom)

^j FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEUTRALIZING ANTIBODY 3BNC 117; UNCLASSIFIED DRUG; 3BNC117 ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY; BLOOD; DRUG; HOMINID; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIVITY; NEUTRALIZATION; VIRUS;

ADULT; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; ARTICLE; BINDING SITE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IMMUNOTHERAPY; INFECTION PREVENTION; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS STRAIN; AMINO ACID SEQUENCE; CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MULTICENTER STUDY; PASSIVE IMMUNIZATION; PROCEDURES; TIME; VIROLOGY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; PRIMATES;

ADULT; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; BINDING SITES; CASE-CONTROL STUDIES; EVOLUTION, MOLECULAR; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; TIME FACTORS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84928405730     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17642     Document Type: Erratum

References (40)

1. Mehandru, S. et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81, 11016-11031 (2007).
2. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Med. 11, 615-622 (2005).
3. Armbruster, C. et al. Passive immunization with the anti-HIV-1 humanmonoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54, 915-920 (2004).
4. Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
5. West, A. P. Jr et al. Structural insights on the role of antibodies inHIV-1 vaccine and therapy. Cell 156, 633-648 (2014).
6. Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
7. Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
8. Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
9. Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanizedmice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).
10. Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921-18925 (2012).
11. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
12. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated frommemory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
13. Scharf, L. et al. Antibody 8ANC195 reveals a site ofbroad vulnerability on theHIV-1 envelope spike. Cell Rep. 7, 785-795 (2014).
14. Falkowska, E. et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657-668 (2014).
15. Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126-138 (2013).
16. Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81-84 (2012).
17. Glassman, P. M. & Balthasar, J. P. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol. Med. 11, 20-33 (2014).
18. Nettles, R. E. et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J. Infect. Dis. 206, 1002-1011(2012).
19. Nimmerjahn, F. & Ravetch, J. V. Antibody-mediated modulation of immune responses. Immunol. Rev. 236, 265-275 (2010).
20. Euler, Z. et al. Cross-reactive neutralizing humoralimmunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201 1045-1053 (2010)
21. Matsushita, S., Yoshimura, K., Ramirez, K. P., Pisupati, J. & Murakami, T. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS 29, 453-462 (2015).
22. Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
23. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
24. Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIVneutralizing antibodies. Nature 509, 55-62 (2014).
25. Klein, F. et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211, 2361-2372 (2014).
26. Deeks, S. G., Lewin, S. R. & Havlir, D. V. The end of AIDS: HIV infection as a chronic disease. Lancet 382, 1525-1533 (2013).
27. Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243-1253 (2014).
28. Diskin, R. et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289-1293 (2011).
29. Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999 (2014).
30. Zhou, T. et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245-258 (2013).
31. Somsouk, M. et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD41 T cell recovery: a randomized crossover trial. PLoS ONE 9, e116306 (2014).
32. Pereyra, F. et al. The major genetic determinants of HIV-1 control affectHLA class I peptide presentation. Science 330, 1551-1557 (2010).
33. Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 12, Unit 12. 11 (2005).
34. Li, M. et al. Human immunodeficiency virus type 1 env clones fromacute and early subtypeBinfections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
35. van 't Wout, A. B., Schuitemaker, H. & Kootstra, N. A. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nature Protocols 3, 363-370 (2008).
36. Laird, G. M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).
37. Salazar-Gonzalez, J. F. et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82, 3952-3970 (2008).
38. Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3. 0. Syst. Biol. 59, 307-321 (2010).
39. West, A. P. Jr. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl Acad. Sci. USA110, 10598-10603 (2013).
40. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188-1190 (2004).